Cardiovascular Disease, Cardiovascular Surgery
Conditions
Keywords
Gut microbiota-derived metabolites, Metabolomics, Cardiovascular disease, Nutritional intervention, Mass spectrometry
Brief summary
This study aims to investigate the distribution of gut microbiota-derived metabolites, and to evaluate whether postoperative nutritional intervention can modulate the gut-heart metabolic axis, thereby improving metabolic profiles and clinical outcomes.
Detailed description
Background： Cardiovascular diseases remain the leading cause of mortality worldwide. Recent research has highlighted the role of gut microbiota and its metabolites-such as trimethylamine-N-oxide, phenylacetylglutamine, and p-cresyl sulfate-in the pathogenesis of cardiovascular disease through mechanisms involving inflammation, oxidative stress, and vascular dysfunction. However, little is known about the actual distribution of these metabolites in human cardiac tissues or their correlation with circulating levels. No clinical studies to date have systematically examined both tissue and blood samples in this context. Methods： Preoperative blood samples and intraoperative cardiac tissue specimens will be collected. Both targeted and untargeted metabolomics analyses will be performed using mass spectrometry to detect key gut microbiota-derived metabolites. A subset of patients will receive postoperative probiotic supplementation. Serial blood will be collected to monitor changes in the metabolome and gut microbial composition.
Interventions
probiotic supplementation will be administered, while participants continue undergoing standard postoperative care
OTHERPlacebo supplementation intervention
Undergo routine standard postoperative care with placebo intervention
Sponsors
Fu Jen Catholic University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Scheduled to undergo cardiovascular surgery * Completed preoperative clinical and imaging evaluations * Willing to provide informed consent * Willing to receive potential probiotic supplementation
Exclusion criteria
* Use of antibiotics, probiotics, or other treatments affecting gut microbiota within 4 weeks * History of major gastrointestinal disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Trimethylamine-N-oxide | From enrollment to the end of intervention at 3 weeks | Gut microbiota-derived metabolites |
| Phenylacetylglutamine | From enrollment to the end of intervention at 3 weeks | Gut microbiota-derived metabolites |
| P-cresyl sulfate | From enrollment to the end of intervention at 3 weeks | Gut microbiota-derived metabolites |
| Indoxyl sulfate | From enrollment to the end of intervention at 3 weeks | Gut microbiota-derived metabolites |
Countries
Taiwan
Contacts
CONTACTKe-Yun Chao, PhD
PRINCIPAL_INVESTIGATORKe-Yun Chao, PhD
Fu Jen Catholic University
Outcome results
None listed